Malignitás társulásának kockázatá t fokozó tényezok vizsgálata myositises betegekben. Klinikai, immunológiai sajátosságok és az anti-p155/140 antitest szerepe

Zsuzsanna Szankai, Melinda Nagy-Vincze, Levente Bodoki, András Jakab, Zoe Betteridge, K. Dankó

Research output: Article

1 Citation (Scopus)

Abstract

Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy. Orv. Hetil., 2014, 155(36), 1437-1444.

Original languageHungarian
Pages (from-to)1437-1444
Number of pages8
JournalOrvosi Hetilap
Volume155
Issue number36
DOIs
Publication statusPublished - szept. 1 2014

Keywords

  • antibodies
  • antitest
  • cancer-associated myositis
  • clinical immunology
  • dermatomyositis
  • klinikai immunológia
  • myositis
  • polymyositis
  • tumorral társuló myositis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Malignitás társulásának kockázatá t fokozó tényezok vizsgálata myositises betegekben. Klinikai, immunológiai sajátosságok és az anti-p155/140 antitest szerepe. / Szankai, Zsuzsanna; Nagy-Vincze, Melinda; Bodoki, Levente; Jakab, András; Betteridge, Zoe; Dankó, K.

In: Orvosi Hetilap, Vol. 155, No. 36, 01.09.2014, p. 1437-1444.

Research output: Article

Szankai, Zsuzsanna ; Nagy-Vincze, Melinda ; Bodoki, Levente ; Jakab, András ; Betteridge, Zoe ; Dankó, K. / Malignitás társulásának kockázatá t fokozó tényezok vizsgálata myositises betegekben. Klinikai, immunológiai sajátosságok és az anti-p155/140 antitest szerepe. In: Orvosi Hetilap. 2014 ; Vol. 155, No. 36. pp. 1437-1444.
@article{05f08e4cb8274a0fbe0b69a79cdc1b28,
title = "Malignit{\'a}s t{\'a}rsul{\'a}s{\'a}nak kock{\'a}zat{\'a} t fokoz{\'o} t{\'e}nyezok vizsg{\'a}lata myositises betegekben. Klinikai, immunol{\'o}giai saj{\'a}toss{\'a}gok {\'e}s az anti-p155/140 antitest szerepe",
abstract = "Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy. Orv. Hetil., 2014, 155(36), 1437-1444.",
keywords = "antibodies, antitest, cancer-associated myositis, clinical immunology, dermatomyositis, klinikai immunol{\'o}gia, myositis, polymyositis, tumorral t{\'a}rsul{\'o} myositis",
author = "Zsuzsanna Szankai and Melinda Nagy-Vincze and Levente Bodoki and Andr{\'a}s Jakab and Zoe Betteridge and K. Dank{\'o}",
year = "2014",
month = "9",
day = "1",
doi = "10.1556/OH.2014.29984",
language = "Hungarian",
volume = "155",
pages = "1437--1444",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Malignitás társulásának kockázatá t fokozó tényezok vizsgálata myositises betegekben. Klinikai, immunológiai sajátosságok és az anti-p155/140 antitest szerepe

AU - Szankai, Zsuzsanna

AU - Nagy-Vincze, Melinda

AU - Bodoki, Levente

AU - Jakab, András

AU - Betteridge, Zoe

AU - Dankó, K.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy. Orv. Hetil., 2014, 155(36), 1437-1444.

AB - Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy. Orv. Hetil., 2014, 155(36), 1437-1444.

KW - antibodies

KW - antitest

KW - cancer-associated myositis

KW - clinical immunology

KW - dermatomyositis

KW - klinikai immunológia

KW - myositis

KW - polymyositis

KW - tumorral társuló myositis

UR - http://www.scopus.com/inward/record.url?scp=84906875702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906875702&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29984

DO - 10.1556/OH.2014.29984

M3 - Article

C2 - 25176518

AN - SCOPUS:84906875702

VL - 155

SP - 1437

EP - 1444

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -